Pre Clinical Oncology Articles & Analysis
10 news found
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. “We are thrilled to welcome Filippo to our executive team,” said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech. “Filippo’s extensive experience in ...
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net sales MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its fully owned subsidiary Constellation Pharmaceuticals, ...
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional ...
Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - Senti Biosciences, Inc. ...
GI Innovation has established an exceptional career in the domestic unlisted bio-industry market, with a total of 250 billion KRW funds, including US$75M from series A to C and US$134M at pre-IPO for global clinical trials. In particular, participation of the major companies, such as SK Corp., Yuhan Corp., iMarketKorea, KDB Bank, NH Investment & Securities, ...
The poster presentations come after Carina’s recent submission of a pre-IND package to the FDA for Carina’s LGR5 CAR-T cell for the treatment of patients with advanced colorectal cancer. Highlights Five conference abstracts will be presented as poster presentations at AACR in the immuno-oncology and preclinical immunotherapy sessions Four ...
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. Our unique technology guarantees fast, reliable, sensitive, and cost-effective results. And it will help you meet the 3Rs guidelines. Learn more and download one of our webinars! Take a step into the future of drug discovery!!! Let’s discover together how ...
Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief ...
Biopticon Corporation Announces the release of the new version of their innovative TumorManagerTM Program for managing pre-clinical oncology study data Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today released the latest version of ...
Biopticon Corporation reaches milestone in market adoption of their innovative Tumor Management System for preclinical oncology studies. Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today announced that it had met its first milestone for customer adoption of the revolutionary ...